AngioDynamics (ANGO) Q4 2026 Earnings
As seen on the 24/7 Wall St. homepage on July 14, 2026.
Q4 2026
EPS
-$0.07
est -$0.09
+22.2%
Revenue
$87M
est $80M
+7.9%
AngioDynamics crushed expectations on both lines as its NanoKnife oncology platform surged 64.5%, driven by newly activated Medicare reimbursement codes that unlock a multi-billion-dollar market. Management guides fiscal 2027 Med Tech growth of 12-15% as the company's shift toward higher-margin platforms continues to pay off.
ANGO share price
Mentioned: ANGO